LONA LeonaBio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1620463 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-313.6%
TTM EPS YoY-129.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-729.0%
ROA-457.7%
ROIC (approx.)-3,861.7%
Asset turnover—
Leverage & solvency
Liabilities / assets58.0%
Debt / equity0.00x
Current ratio4.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.49x
Accruals ratio-234.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $17.50M | $70.68M |
| SG&A expense | $16.68M | $26.09M |
| Operating income | -$102.27M | -$100.90M |
| Pretax income | -$105.61M | -$96.91M |
| Income tax | $0 | — |
| Net income | -$105.61M | -$96.94M |
| EBITDA | -$101.29M | -$99.93M |
| EPS (basic) | -24.70 | -25.19 |
| EPS (diluted) | -24.70 | -25.19 |
| Weighted avg. shares (diluted) | 4.28M | 3.85M |
| Balance sheet | ||
| Cash & equivalents | $69.28M | $48.44M |
| Short-term investments | $19.05M | $2.84M |
| Current assets | $89.46M | $54.84M |
| PP&E, net | $1.47M | $2.44M |
| Total assets | $92.15M | $58.78M |
| Current liabilities | $47.50M | $13.13M |
| Total liabilities | $64.36M | $13.94M |
| Shareholders' equity | $27.79M | $44.84M |
| Shares outstanding | 9.34M | 3.90M |
| Cash flow statement | ||
| Operating cash flow | -$45.73M | -$97.17M |
| Capital expenditure | — | $33,000 |
| Free cash flow | — | -$97.20M |
| Investing cash flow | -$15.89M | $54.83M |
| Financing cash flow | $82.46M | $194,000 |
| Depreciation & amortization | $972,000 | $970,000 |
| Stock-based compensation | $6.10M | $11.05M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.